One touch 2 blood glucose monitoring system

Some arterial blood (180 μL) was used to analyse the levels of pH, carbon dioxide tension (PaCO₂), bicarbonate (HCO₃^-), base excess and potassium concentration by an arterial blood gas analyzer (AVL OPTI Critical Care Analyzer, AVL Scientific Corp., Roswell, GA, USA). Blood glucose was analysed by a One-Touch II blood glucose monitoring system (Lifescan Inc., Milpitas, CA, USA) with 10 μL of whole blood. The remaining blood was then immediately centrifuged at 7,500 g for 2 minutes to obtain the plasma. Plasma (80 μL) was used to analyse the biochemical parameters of liver and kidney function. Liver function was assessed by measuring plasma levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT), and renal function was assessed by plasma levels of blood urea nitrogen (BUN) and creatinine. In addition, plasma lactate dehydrogenase (LDH) was measured to evaluate the extent of organ injury. All of these biochemical parameters were analysed by Fuji DRI-CHEM 3030 (Fuji Photo Film Co., Ltd., Tokyo, Japan).

We used an MK-2000A blood pressure monitor (Muromachi Kikai, Tokyo, Japan) to detect baseline SBP and HR and those 24 h after saline or LPS administration. In addition, 10 μl of whole blood was taken to evaluate the glucose levels using a One Touch II blood glucose monitoring system (Lifescan, Milpitas, CA, USA).

Before the blood sample was centrifuged to prepare serum, ten microliters of whole blood was taken to measure the glucose level in blood by a One Touch II blood glucose monitoring system (Lifescan, Milpitas, CA, USA). One hundred and eighty microliters of whole blood was used to examine the levels of HCO₃^-, BE, PaCO₂, and PaO₂ by an arterial blood gas analyzer (AVL OPTI Critical Care Analyzer, AVL Scientific Corp., Roswell, GA, USA).